03rd week of 2012 patent applcation highlights part 43 |
Patent application number | Title | Published |
20120015834 | METHODS FOR ARTIFICIAL COMBINATORIAL CONTROL OF BIOLOGICAL SYSTEMS - Methods and systems for determining a set of control molecules for use in a combinatorial approach for the treatment of medical conditions, including providing one or more sets of control molecules, where each control molecule within the set acts on a set of targets and the number of control molecules within the one or more sets of control molecules is fewer than the number of targets within the sets of targets; and searching within the sets of control molecules to identify a subset of control molecules that together with a subset of targets form an artificial system to produce a biological effect through the modulation of the subset of targets. | 2012-01-19 |
20120015835 | Devices and Methods for Enrichment and Alteration of Circulating Tumor Cells and Other Particles - The invention features devices and methods for detecting, enriching, and analyzing circulating tumor cells and other particles. The invention further features methods of diagnosing a condition, e.g., cancer, in a subject by analyzing a cellular sample from the subject. | 2012-01-19 |
20120015836 | KITS FOR MULTIPLEXED NUCLEIC ACID ANALYSIS BY CAPTURE OF SINGLE-STRANDED DNA PRODUCED FROM DOUBLE-STRANDED TARGET FRAGMENTS - A method of fragmentation of double stranded DNA is disclosed for use in nucleic acid analysis, notably in the multiplexed analysis of polymorphisms and mutations. The method produces a multiplicity of labeled sense and anti-sense fragments which are not complementary, and thus do not significantly re-anneal under conditions suitable for hybridization analysis (or capture-mediated elongation analysis) of the polymorphisms and/or mutations. The fragments display a desired or predicted length distribution. Cleavage sites can be selected such that the fragments are short, yet long enough to allow discrimination among fragments in an assay, and as a matter of statistical probability, such that the majority of fragments contain at least one labeled nucleotide to facilitate detection. | 2012-01-19 |
20120015837 | METHOD FOR DIAGNOSING ENDOMETRIAL CANCER - An object of the present invention is to provide a method for diagnosing endometrial cancer by comprehensively analyzing the glycan structures of glycoprotein with the normal endometrium and endometrial cancers (well-differentiated/poorly-differentiated), using the lectin microarray system. The present invention provides a method for diagnosing or determining the state of normal endometrium or endometrial cancer/cancer stages by glycan profiling using a structure of a glycoprotein in a sample as an indicator. | 2012-01-19 |
20120015838 | Method and Kit for Diagnosing Autism Using Gene Expression Profiling - This invention relates to DNA microarray technology, and more specifically to methods and kits for identifying autism and autism spectrum disorders in humans. | 2012-01-19 |
20120015839 | RECURRENT GENE FUSIONS IN CANCER - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions as diagnostic markers and clinical targets for cancer (e.g., prostate cancer). | 2012-01-19 |
20120015840 | METHODS FOR GENERATION OF RNA AND (POLY)PEPTIDE LIBRARIES AND THEIR USE - The present invention relates to a method for generating an RNA library or a (poly)peptide library comprising the steps of: (a) providing one or more nucleic acid molecules each comprising i) two or more coding elements (A) each giving rise to an RNA molecule upon transcription and/or a (poly)peptide upon transcription and translation; and ii) linking elements (B) arranged according to the general formula of B(AB) | 2012-01-19 |
20120015841 | NOVEL CELL LINES AND METHODS - The invention relates to novel cells and cell lines, and methods for making and using them. | 2012-01-19 |
20120015842 | Enumeration Of Nucleic Acids - Disclosed are methods and systems for enumeration of nucleic acids, including for the detection of rare events in a biological sample. In certain embodiments, the method may comprise arranging polynucleotides obtained from a biological sample to form a plurality of reaction sites, wherein each reaction site contains on average one polynucleotide; amplifying the polynucleotides in the plurality of reaction sites; determining by nucleic acid hybridization (i) a first number of first reaction sites containing a target nucleic acid sequence, or a portion thereof, and (ii) a second number of second reaction sites containing a reference nucleic acid sequence, or a portion thereof; comparing the first number of the first reaction sites to the second number of the second reaction sites to determine the relative amount of the target nucleic acid in the biological sample. | 2012-01-19 |
20120015843 | GENE AND GENE EXPRESSED PROTEIN TARGETS DEPICTING BIOMARKER PATTERNS AND SIGNATURE SETS BY TUMOR TYPE - Provided herein are methods and systems for identifying a therapeutic for an individual, such as a therapeutic not previously identified for treating the individual. The therapeutic can be identified by molecular profiling, such as determining the biomarker patterns or signature sets of a biological sample of an individual. | 2012-01-19 |
20120015844 | DEVICE AND METHOD FOR PRODUCING A REPLICATE OR DERIVATIVE FROM AN ARRAY OF MOLECULES, AND APPLICATIONS THEREOF - A method of producing a replicate or derivative of an array of molecules, the array having a spatial arrangement of separate samples of molecules, includes creating, for each sample, at least one spatially limited effective area which is separate from the effective areas of the other samples, a surface, provided with a binding adapter or binding properties, of a carrier bordering on the effective areas. The molecules are amplified by means of amplifying agents in the effective areas for creating replicates or derivatives of the samples. The replicates or derivatives of the samples are bound to the carrier by means of the binding adapter or the binding properties, so that a spatial arrangement of the replicates or derivatives of the samples on the carrier corresponds to the spatial arrangement of the samples in the array. The carrier having the copies of the samples is removed from the array. | 2012-01-19 |
20120015845 | MARKERS FOR THE DIAGNOSIS OF AML, B-ALL AND T-ALL - Disclosed are diagnostic markers specific for acute myeloid leukemia (AML), B-cell lineage acute lymphoblastic leukemia (B-ALL), and T-cell lineage acute lymphoblastic leukemia (T-ALL). Also disclosed are a composition and a kit, comprising an agent detecting the presence of the markers, and a method of diagnosing AML, B-ALL and T-ALL using the same. | 2012-01-19 |
20120015846 | Label-free Cellular Pharmacology For Drug Antitarget Assessment - Described are methods relating to assessing antitargets of molecules. Also described are methods of screening molecules. In some aspects of the methods, the molecules are analyzed using a label free biosensor. | 2012-01-19 |
20120015847 | DIAGNOSIS OR PROGNOSIS OF LUNG CANCER AND COLORECTAL CANCER BASED ON EXPRESSION LEVEL OF GLUTAREDOXIN 3 - The present invention relates to a biomarker for diagnosing lung cancer and colorectal cancer containing glutaredoxin 3 as an active ingredient, and a kit for diagnosing lung cancer and colorectal cancer using the same biomarker. Glutaredoxin 3 of the present invention is over-expressed in lung cancer tissue and colorectal cancer tissue, which enables early prediction of diagnosis or prognosis of lung cancer and colorectal cancer. Thus, glutaredoxin 3 can be helpfully used as a biomarker for diagnosing lung cancer and colorectal cancer. | 2012-01-19 |
20120015848 | DISPOSABLE REACTION VESSEL WITH INTEGRATED OPTICAL ELEMENTS - The present invention provides disposable, semi-reusable, or single use reaction vessels with integrated optical elements for use with diffraction based assay systems. The vessel for assaying liquids for analytes includes a housing having at least one chamber or well for receiving a liquid therein and an optical element integrally formed with the housing for directing an incident light beam towards the well or chamber and directing a light beam away from the chamber after the light beam has interacted with analytes present in the liquid. The vessel may be test tube such as a blood collection tube, with or without, an optical element but having a pattern of analyte-specific receptors located on an inner surface of the tube wall so that when a liquid is introduced into the interior of the test tube analytes present in the liquid can bind with the pattern of analyte-specific receptors. | 2012-01-19 |
20120015849 | Method of Creating a Library of Bacterial Clones with Varying Levels of Gene Expression - The present invention relates to a method of creating DNA libraries that include an artificial promoter library and/or a modified ribosome binding site library and transforming bacterial host cells with the library to obtain a population of bacterial clones having a range of expression levels for a chromosomal gene of interest. | 2012-01-19 |
20120015850 | siRNA targeting Superoxide - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for SOD1. | 2012-01-19 |
20120015851 | METHOD AND DEVICE FOR RAPID, DETECTION OF SPECIFIC REACTIONS USING NON-MAGNETIC AND MAGNETIC NANOPARTICLES - A method and apparatus for conducting specific binding assays with two or more particles is claimed. A non-magnetic nanoparticle capable of binding the target of interest is mixed with a magnetic particle capable of binding a species directed toward binding the same target of interest. Following the application of the mixture to a capillary tube or other container that allows the separation with a magnetic field or other force, the resultant movement of the magnetic or combination of magnetic and non-magnetic assemblies can be read visually or with the aid of an appropriate instrument. | 2012-01-19 |
20120015852 | Nanofluids and Methods of Use for Drilling and Completion Fluids - Nanomaterial compositions are useful for applications in drilling and completion fluids as enhancers of electrical and thermal conductivity, emulsion stabilizers, wellbore strength improvers, drag reduction agents, wettability changers, corrosion coating compositions and the like. These nanomaterials may be dispersed in the liquid phase in low volumetric fraction, particularly as compared to corresponding agents of larger size. Nanofluids (fluids containing nano-sized particles) may be used to drill at least part of the wellbore. Nanofluids for drilling and completion applications may be designed including nanoparticles such as carbon nanotubes. These fluids containing nanomaterials, such as carbon nanotubes, meet the required rheological and filtration properties for application in challenging HPHT drilling and completions operations. | 2012-01-19 |
20120015853 | OVERBASED MAGNESIUM OXIDE DISPERSIONS - Overbased MgO dispersions with high magnesium content and acceptably low viscosities are reproducibly prepared without gel formation by heating to 280-360° C. a mixture of MgO, selected dispersants, low MW carboxylic acids, water and a combination of high boiling hydrocarbon and organic diluent, wherein water is more than 8%, typically more than 10% of the reaction mixture. No additional solubilizing or dispersing agents, promoters or reactants such as carbon dioxide, amines, alcohols etc are needed to obtain the desired dispersions. Compositions such as lubricating oils and fuels containing the overbased magnesium dispersions as additives are also disclosed. | 2012-01-19 |
20120015854 | Olefinic Copolymer Compositions for Viscosity Modification of Motor Oil - Lube oil compositions and methods for making the same are provided. The lubricating oil composition can include at least one propylene-based polymer comprising 60 wt % to 98 wt % propylene derived units, other units derived from one or more other alpha olefins, and a base oil. The propylene-based polymer can have a triad tacticity of 90% or more, a heat of fusion of less than 80 J/g, and a weight average molecular weight (Mw) as measured by GPC of from 70,000 to 250,000. | 2012-01-19 |
20120015855 | Amine Derivatives as Friction Modifiers in Lubricants - A composition is provided for use as a friction modifier for an automatic transmission, comprising a long chain hydrocarbyl amine having one or two additional groups on one or two different amine nitrogen atom thereof of the structure —R3-C(=0)X(R4)c. R3 is an alkylene group or a group comprising a group of 1-4 carbon atoms or a chain of 2 to 9 carbon atoms interrupted by one or two nitrogen or oxygen atoms within the chain; X is nitrogen or oxygen, and R4 is a long chain hydrocarbyl group, or H, or —R3-NHR5. The compound does not contain a primary amino group. | 2012-01-19 |
20120015856 | UNIVERSAL AQUEOUS CLEANING SOLUTION FOR ELECTRIC SHAVERS - The present disclosure generally relates to a method for cleaning a shaving device using a cleaning solution and preparation of the cleaning solution. More particularly, the present disclosure relates to a method of cleaning a shaving device using an environmentally friendly cleaning solution. | 2012-01-19 |
20120015857 | LITHOGRAPHIC TOOL IN SITU CLEAN FORMULATIONS - Compositions and methods of using said composition for removing polymeric materials from surfaces, preferably cleaning contaminant buildup from a lithography apparatus without total disassembly of said apparatus. | 2012-01-19 |
20120015858 | CLEANING AGENT - The invention relates to a packed form of a washing or cleaning agent comprising (a) a first liquid washing or cleaning agent preparation A comprising (i) builder and (ii) complexing agent; (b) a second liquid washing or cleaning agent preparation B, of different composition than preparation A, comprising (i) greater than 1 wt. % water; (ii) at least 5 wt. % of at least one active washing or cleaning enzyme preparation; (iii) less than 10 wt. % phosphate; and (iv) less than 2.5 wt. % complexing agent; and (c) a packaging means, in which the washing or cleaning agent preparations A and B are contained and physically separate from one another, and wherein the inventive packaged form of a washing or cleaning agent is characterized by good storage stability and temperature stability, and good washing and cleaning performance. | 2012-01-19 |
20120015859 | FLUID BLEACHING AGENT COMPOSITION - The invention relates to an aqueous, fluid washing or cleaning agent comprising bleaching agent, comprising hydrogen peroxide and nonionic surfactant in the form of an alkoxylated alcohol and anionic surfactant, wherein the weight ratio of alkoxylated alcohol to anionic surfactant is in the range from 1:1 to 5:1, in particular 2:1 to 4:1, and the agent comprises a paraffin hydrocarbon. | 2012-01-19 |
20120015860 | GENTLE BLEACHING AGENT - The aim of the invention is reduce the damage to material containing cellulose during the bleaching thereof, by using bleaching catalysts, without significantly affecting the bleaching performance. This is achieved essentially by a method for the bleach treatment of material containing cellulose in the presence of a bleaching agent containing peroxygen and a bleach-enhancing transition metal complex, said method being carried out in the presence of a saccharide polymer carrying carboxy groups. | 2012-01-19 |
20120015861 | POLYMERS FOR LAUNDRY DETERGENTS - A detergent composition having at least two components. The first component is from 8 to 50 wt % surfactants. The second component is from 0.05 to 4 wt % of a polymer which has polymerized residues of 40 to 80 wt % C | 2012-01-19 |
20120015862 | Cleaning Solution - Disclosed are cleaning solutions. More particularly, non-toxic solutions of base, water, alcohol and detergent, that effectively and surprisingly eliminate contaminating aliphatic acids in aqueous solutions. When present as a foam or even a contaminating film remaining on various parts and surfaces, aliphatic acid contaminants can be present a large and costly problem in manufacturing operations, cleaning tasks, personal hygiene. The need to remove such contaminants arises in a myriad environments and situations, such as during the manufacture of detergents, pharmaceuticals, consumer products, coring and core analysis, manipulation of oils, fuels, fermentation applications, manufacture of emollients, moisturizers, liquors, foods such as seafood, milk, butter and other dairy products, water processing, paper products, tissue culture, reusable clinical equipment, and the like. Presented are cleaning compositions and methods that effectively eliminate and prevent build up of such dangerous and costly contaminants in aqueous solutions. | 2012-01-19 |
20120015863 | CLEANING COMPOSITIONS AND METHODS - The invention provides solvent and cleaning compositions comprising an ionic surfactant, which preferably has a fluorinated portion thereof, and a solvent selected from hydrofluoro- and/or hydrochlorofluoro-olefins. Additionally, the invention provides drying, dry cleaning, and soil repellency compositions containing a hydrofluoro- or hydrochlorofluoro-olefin and said surfactant. Additionally, the invention provides drying compositions containing a hydrofluoro-olefin or hydrochlorofluoro-olefin and an alcohol such as methanol, ethanol or isopropanol. | 2012-01-19 |
20120015864 | Low Solids, High Viscosity Fabric Softener Compositions and Process for Making the Same - Disclosed are low solids and high viscosity fabric softener compositions and processes for preparing them. The composition contains from about 0.05% to about 10% by weight of a rheology modifying fabric softening active comprising at least one long chain amine of the present technology, a derivative thereof, or a mixture thereof, and from about 1% to 10% by weight of an additional fabric softening active dispersed in water. | 2012-01-19 |
20120015865 | NOVEL CLASS OF CATIONIC LIPIDS FOR TRANSPORTING ACTIVE AGENTS INTO CELLS - A subject of the present invention is the development of a novel family of cationic lipids and their use as vectors for in vitro, ex vivo and in 5 vivo delivery of biologically active agents. | 2012-01-19 |
20120015866 | Prodrugs of Heteraromatic Compounds - The present invention relates to prodrugs of parent drug compounds containing heteroaromatic NH groups. | 2012-01-19 |
20120015867 | THERAPEUTIC PEPTIDES AND METHOD - A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterised by the ability to treat, ameliorate, or lessen the symptoms of conditions including sepsis, septic shock or sepsis-like conditions and IBD. | 2012-01-19 |
20120015868 | Metastin derivatives and use thereof - The present invention provides a metastin derivative in which the amino acids comprising metastin were modified by alternative chemical substituents resulting in metastin derivitives, having excellent blood stability and exhibiting cancer metastasis inhibiting action or cancer growth inhibiting action. | 2012-01-19 |
20120015869 | ANTIMICROBIAL AQUEOUS SOLUTION AND ITS PREPARATION METHOD - The antimicrobial aqueous solution of the present invention comprises an original undiluted aqueous solution containing: 25 μg/ml to 50 μg/ml of an amphipathic preservative comprising a monoglycerol monolaurate; and 12.5 μg/ml to 30 μg/ml of an ε-polylysine. In preparing the antimicrobial aqueous solution, dissolution of the amphipathic antimicrobial can be promoted by addition of a sucrose monolaurate and by heating to 35° C. to 60° C. This antimicrobial aqueous solution can be used effectively, even within a range of concentrations lower than concentrations to be typically used for amphipathic antimicrobials. It is possible to adopt a diglycerol monolaurate, instead of the monoglycerol monolaurate. | 2012-01-19 |
20120015870 | PEPTIDES AND COMPOSITIONS FOR PREVENTION OF CELL ADHESION AND METHODS OF USING SAME - Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of FDYDWY (SEQ ID NO: 2), SFSQNKSVHSFDYDWYNVSDQADLKN (SEQ ID NO: 3) or CSFSQNKSVHSFDYDWYNVSDQADLKNC (SEQ ID NO: 1), or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface. | 2012-01-19 |
20120015871 | COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS - Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system. | 2012-01-19 |
20120015872 | COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS - Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system. | 2012-01-19 |
20120015873 | MELANOCORTIN ANALOGS WITH ANTIMICROBIAL ACTIVITY - The present invention finds application in the therapeutic fields. In particular, it concerns new synthetic melanocortin peptides having improved antimicrobial activity. | 2012-01-19 |
20120015874 | NOVEL INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTACE - Disclosed are nucleic acid molecules, and methods of their use, which have a specific structure including a double helical domain and a G-quadruplex domain physically connected by a linker domain which may be nucleosidic or non-nucleosidic. These aptamers demonstrate potent inhibition of phylogenetically diverse primate lentiviral reverse transcriptases, which effect is largely independent of aptamer sequence provided that the aptamer has the specified structure. | 2012-01-19 |
20120015875 | Use Of Oxandrolone In The Treatment Of Burns And Other Wounds - The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient. | 2012-01-19 |
20120015876 | CONJUGATES OF GLP-1 AGONISTS AND USES THEREOF - The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a GLP-1 agonist (e.g., exendin-4 or an exendin-4 analog). The compounds of the invention can be used to treat any disease where increased GLP-1 activity is desired, for example, metabolic diseases, such as obesity and diabetes. | 2012-01-19 |
20120015877 | USE OF GDF TRAPS TO INCREASE RED BLOOD CELL LEVELS - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 2012-01-19 |
20120015878 | USE OF ADNF POLYPEPTIDES FOR TREATING ANXIETY AND DEPRESSION - This invention relates to the use of ADNF polypeptides in the treatment of anxiety and/or depression. The present invention also relates to drug discovery assays using the ADNF polypeptide mechanism of action and target interaction, as well as the manufacture of medicaments, methods of application and formulation therefor. Embodiments of the invention provide methods for preventing and/or treating anxiety and depression disorders in a subject by administering a NAP, an 8-amino-acid peptide derived from Activity Dependent Neurotrophic Factor (ADNF III), in an amount sufficient to improve postnatal performance. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites and provide neuroprotective and anti-anxiety functions. | 2012-01-19 |
20120015879 | Unitary combinations of FSH and hCG - A novel ovulatory induction paradigm entails administration of hCG in combination with FSH during all stages of treatment, where the ratio of FSH to hCG is adjusted to optimize ovulatory stimulation and minimize complications. The use of compositions characterized by various FSH:hCG ratios enables the practitioner readily to tailor the treatment regimen and accommodate different therapeutic goals as well as individual patient responses to gonadotropin administration. | 2012-01-19 |
20120015880 | INTRANASAL DESMOPRESSIN ADMINISTRATION - Disclosed is a family of intranasal spray dispensers for administering uniform low doses of desmopressin so as to achieve safe antidiuresis in human patients. The dispensers of the invention may be used in the treatment of nocturia, primary nocturnal enuresis, incontinence, urinary frequency, diabetes insipidus, or any disease or syndrome where desmopressin therapy is useful or where safe temporary suppression of urine production may lead to beneficial health effects or increased convenience in voiding control. | 2012-01-19 |
20120015881 | KALLIKREIN-INHIBITOR THERAPIES - Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient. | 2012-01-19 |
20120015882 | COMPOSITION FOR REGULATING AUTONOMIC NERVOUS ACTIVITY AND METHOD FOR REGULATING AUTONOMIC NERVE - The present invention provides an orally ingestible composition and a method for regulating an autonomic nervous activity. In particular, the present invention provides an orally ingestible composition capable of suppressing an increase in a sympathetic nervous activity, and an orally ingestible composition capable of promoting a parasympathetic nervous activity. The present invention is a composition for regulating an autonomic nervous activity, comprising, as an active ingredient, Tyr-Pro or a salt thereof. | 2012-01-19 |
20120015883 | Peptoid and synthetic oligomers, pharmaceutical compositions and methods ofusing same - Novel peptide/peptoid oligomers are disclosed that have a formula represented by the following formula Ia or Ib: | 2012-01-19 |
20120015884 | Polypeptides for Specific Targeting to Otx2 Target Cells - The invention relates to polypeptides which enable the specific targeting of a molecule of interest to homeoprotein Otx2 target cells. These polypeptides are defined by the general sequence: B | 2012-01-19 |
20120015885 | COMPOSITIONS AND METHODS FOR CaMKII INHIBITORS AND USES THEREOF - Embodiments herein generally relate to methods, compositions and uses of CaMKII inhibitors. Other embodiments relate to methods, compositions and uses of agents that target CaMKII. Yet further embodiments relate to compositions, methods and uses of CaMKIIN-derived molecules and other CaMKII inhibitor molecules that inhibit autonomous CaMKII activity. In accordance with these embodiments, compositions that inhibit autonomous CaMKII activity may be used for treating conditions causing neuronal cell death, for treating cancer or for treating neurodegenerative disorders. | 2012-01-19 |
20120015886 | METHOD FOR PREPARING RECOMBINANT PEPTIDE FROM SPIDER VENOM AND METHOD FOR RELIEVING PAIN - The present invention relates to a method for producing a recombinant, spider toxin peptide and analgesic compositions containing said peptide. More specifically, the present invention relates to a method in which the gene for GsMTx4 is subcloned into a vector, so that it is linked to a secretion signal sequence of the alpha factor and under the control of methanol-inducible alcohol oxidase (AOX) promoter to construct a recombinant yeast expression plasmid. Yeast cells are transformed with this plasmid to produce the GsMTx4 peptide and analgesic compositions containing said peptide. The recombinant yeast expression system of the present invention affords a more stable method for producing GsMTx4 than its natural route. Thus the GsMTx4 peptide and its derivatives produced by the method of this invention can be used in the cure of related diseases such as heart failure as the peptide specifically inhibits mechanosensitive ion channels. | 2012-01-19 |
20120015887 | SYNTHETIC PEPTIDE AND USES THEREOF - A 4-copy branched peptide represented by a formula of (X | 2012-01-19 |
20120015888 | T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides T cell receptors (TCRs) having antigenic specificity for a cancer antigen, e.g., tyrosinase. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials. | 2012-01-19 |
20120015889 | METHOD FOR THE ADMINISTRATION OF LIGANDS, AGONISTS OF LIGANDS OF THE TNF FAMILY WITH REDUCED TOXICITY - The present invention concerns the use of a multimerized form of ligands of the TNF family for the preparation of a medicament for injection into an appropriate cavity of the body, for the treatment of diseases wherein cell proliferation has to be controlled wherein the ligand of the TNF family is selected among Fas ligand, CD40L, TRAIL and APRIL. | 2012-01-19 |
20120015890 | Use of Soluble Forms of CD83 and Nucleic Acids Encoding them for the Treatment or Prevention of Diseases - The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving dendritic cells, T cells and/or B cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies. | 2012-01-19 |
20120015891 | DEPOT SYSTEMS COMPRISING GLATIRAMER OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF - The present invention provides long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer. In particular, the present invention provides a long acting pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection. | 2012-01-19 |
20120015892 | FORMULATIONS OF CANFOSFAMIDE AND THEIR PREPARATION - This invention provides stable, lyophilized formulations of canfosfamide as well as the methods of preparation of those stable lyophilized formulations. | 2012-01-19 |
20120015893 | FORMULATIONS CONTAINING SORBITAN CARBOXYLIC ACID ESTER - The invention relates to formulations for the washing and care of human or animal body parts, said formulations containing sorbitan carboxylic acid esters and characterized in that the carboxylic acid part of the sorbitain carboxylic acid ester is derived from a carboxylic acid containing between 6 and 10 carbon atoms and the sorbitan carboxylic acid esters have a hydroxyl count (OH count) of higher than 350. The invention also relates to the use of sorbitan carboxylic acid ester in washing or care formulations. | 2012-01-19 |
20120015894 | AQUEOUS HAIR CLEANSING AGENT - An aqueous hair cleansing agent contains a sulfate-type anionic surfactant having a specific structure, an ether carboxylate-type anionic surfactant having a specific structure, and an organic carboxylic acid or salt thereof, thereby has a pH of 1 to 5 at 25° C. when diluted 20-fold with water. | 2012-01-19 |
20120015895 | Use Of RR/SR-Ractopamine - A method of promoting or improving the feed efficiency and the muscle-to-fat ratio in animals by administering to the animals a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed. Manufacturing methods for making RR/SR-ractopamine are presented. | 2012-01-19 |
20120015896 | Anti-Penicillin Resistant Pneumococci Agent and Novel 16-Membered Macrolide Derivative - A novel compound that has antimicrobial activity against penicillin-resistant | 2012-01-19 |
20120015897 | NOVEL FORMULATION FOR TREATING FUNGAL INFECTIONS - A novel formulation for treating fungal infections comprising Cholesterol containing Nanosomal Amphotericin B in a Saline Suspension | 2012-01-19 |
20120015898 | COMPOUNDS AND METHODS FOR TREATMENT OF SICKLE CELL DISEASE OR COMPLICATIONS ASSOCIATED THEREWITH - Compounds, compositions and methods are provided for treatment of sickle cell disease or a complication associated therewith, or graft versus host disease, in an individual. More specifically, the use of particular glycomimetics for the treatment is described. | 2012-01-19 |
20120015899 | MODIFIED PLANT VIRUS PARTICLES AND USES THEREFOR - Aspects of the invention provide modified virus-like particles that are designed for therapeutic applications. In particular, aspects of the invention provide CCMV coat proteins that are modified to generate virus-like particles, including mosaic virus-like particles, that can package and/or deliver one or more diagnostic and/or therapeutic agents. The invention also provides methods for treating subjects with one or more modified virus-like particles. | 2012-01-19 |
20120015900 | Cobalamin Taxane Bioconjugates - The present invention is directed to methods and compositions including a taxane covalently bonded to the cobalt atom of a cobalamin. The composition can be delivered by any effective route, but is particularly useful as an oral anti-cancer or antiangiogenic compound. The anti-cancer/anti-angiogenic compound can be used in various chemotherapies including anti-angiogenic chemotherapies, alone or in combination with other anti-cancer/anti-angiogenic compounds. | 2012-01-19 |
20120015901 | METHODS AND PREPARATIONS FOR PROTECTING CRITICALLY ILL PATIENTS - The present invention relates to a method of treating a life threatening condition in a critically ill human patient with a non-infectuous disorder, wherein the critically ill patient is a patient receiving enteral or parenteral nutrition, the method comprising the step of administering to said patient an autophagy inducing agent. | 2012-01-19 |
20120015902 | ARABINOXYLO-OLIGOSACCHARIDES USEFUL AGAINST GASTROINTESTINAL INFECTIONS - The present invention relates to the use of oligosaccharides derived from arabinoxylan for use in the prevention and treatment of gastrointestinal infection. More particularly the invention provides a method for preventing or reducing the gastrointestinal infection of a animal or human being with bacteria associated with gastroenteritis through the supplementation of their diets with the said oligosaccharides. | 2012-01-19 |
20120015903 | PHARMACEUTICAL COMPOSITION FOR INHIBITING INCREASE OF IgA - The present invention discloses a pharmaceutical composition for inhibiting increase of immunoglobulin A (IgA) comprising β-glucan and a pharmaceutical acceptable carrier. The β-glucan is extracted from | 2012-01-19 |
20120015904 | BIOMARKERS FOR DIAGNOSIS OF TRANSIENT ISCHEMIC ATTACKS - The present invention provides methods and compositions for diagnosing and predicting the risk and cause of transient ischemic attacks (TIA). | 2012-01-19 |
20120015905 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES - The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. | 2012-01-19 |
20120015906 | USES OF BORTEZOMIB IN PREDICTING SURVIVAL IN MULTIPLE MYELOMA PATIENTS - The present invention provides a method of predicting outcome of treatment for multiple myeloma based on determining certain cytogenetic anomalies and considering gene expression profiling risks. Also provided are statistical methods employed to define variables independently impacting outcomes. Further provided is method of treatment of myeloma patients. | 2012-01-19 |
20120015907 | Furopyridine compounds and uses thereof - The present invention provides a compound of formula I; | 2012-01-19 |
20120015908 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES - A compound of Formula I is disclosed as follows: | 2012-01-19 |
20120015909 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY - The invention provides novel compounds of formulae I and II: | 2012-01-19 |
20120015910 | Synergistic fungicidal active substance combinations - Novel active compound combinations comprising a carboxamide of the general formula (I) (group 1) | 2012-01-19 |
20120015911 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES - Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. | 2012-01-19 |
20120015912 | USE OF 2,5-DIHYDROXYBENZENE FOR THE TREATMENT OF OCULAR DISEASES - The present invention relates to the use of a compound of Formula (I | 2012-01-19 |
20120015913 | Formulations of 14-EPI-Analogues of Vitamin D - The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile. | 2012-01-19 |
20120015914 | FORMULATIONS OF 14-EPI-ANALOGUES OF VITAMIN D - The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile. | 2012-01-19 |
20120015915 | FORMULATIONS OF 14-EPI-ANALOGUES OF VITAMIN D - The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile. | 2012-01-19 |
20120015916 | Method for Treating Secondary Hyperparathyroidism in CKD - A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation. | 2012-01-19 |
20120015917 | Use of Estrogenic Compounds in Combination with Progestogenic Compounds in Hormone-Replacement Therapy - The present invention relates to a pharmaceutical kit comprising a plurality of oral dosage units which comprise a progestogen. The progestogen is levonorgestrel, norgestimate, norethisterone, drospirenone, dydrogesterone, trimegestone, dienogest, precursors thereof and mixtures thereof. The kit comprises an amount of progestogen equivalent to 30-500 mg of levonorgestrel, 1-40 mg of ethinyl estradiol and 02-100 mg dehydroepiandrosterone. | 2012-01-19 |
20120015918 | Lipolytic Methods for Regional Adiposity - Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally. | 2012-01-19 |
20120015919 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND AROMATASE INHIBITORS OR COMBINATIONS OF COX-2 INHIBITORS AND ESTROGEN RECEPTOR ANTAGONISTS - Described herein are compositions and methods for using these compositions in the treatment of cancer, tumors, and tumor-related disorders in a subject. | 2012-01-19 |
20120015920 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS - The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors. | 2012-01-19 |
20120015921 | PHARMACEUTICAL FORMULATIONS:SALTS OF 8-[1-3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXYMETHYL]-8-PHENYL-1,7-DIAZA-SP- IRO[4.5]DECAN-2-ONE AND TREATMENT METHODS USING THE SAME - Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms. | 2012-01-19 |
20120015922 | USE OF ARTEMISININ DERIVATIVES FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - Artesunate is a derivative of artemisinin isolated from a Chinese herb | 2012-01-19 |
20120015923 | USE OF ANDROGRAPHOLIDE COMPOUNDS FOR TREATING INFLAMMATION AND AIRWAY DISORDERS - We describe for the first time that andrographolide derivatives such as DDAG effectively reduced OVA-induced inflammatory cell recruitment into BAL fluid, IL-4, IL-5, IL-13 and eotaxin production, serum IgE synthesis, pulmonary eosinophilia, mucus hypersecretion and AHR in a mouse asthma model potentially via inhibition of NF-?B activity. Moreover, low dose of DDAG and glucocorticoid combination treatment synergistically attenuate inflammation in mouse asthma model. These findings support a therapeutic value for DDAG in the treatment of asthma. | 2012-01-19 |
20120015924 | SPRAY-DRYING PROCESS - The process comprises delivering a spray solution comprising an active agent and a matrix material in an organic solvent to a spray-drying apparatus, atomizing the spray solution into droplets within the spray-drying apparatus to remove at least a portion of the organic solvent from the droplets to form a plurality of particles, and collecting the particles. The spray solution may be formed by forming a feed suspension comprising the active agent, the matrix material, and the organic solvent, wherein the feed suspension is at a temperature T | 2012-01-19 |
20120015925 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS - A pharmaceutical useful as a therapeutic agent and a preventive agent for hyperlipemia, and a pharmaceutical useful as a therapeutic agent and a preventive agent for hepatic disorders associated with cholestasis, particularly, primary biliary cirrhosis and primary sclerosing cholangitis, and a pharmaceutical useful as a therapeutic agent and a preventive agent for obesity, fatty liver and steatohepatitis are provided. A benzothiazepine or benzothiepine compound represented by the following formula (1A) having a thioamide bond and a quaternary ammonium substituent: | 2012-01-19 |
20120015926 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof. | 2012-01-19 |
20120015927 | CRYSTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENYL)METHYL]THIO]-6--4-PYRIMIDINYL]-1-AZETIDINESULF- ONAMIDE - There is provided crystalline forms of N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]1-azetidinesulfon-amide anhydrate. Such compounds/forms may be useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial. | 2012-01-19 |
20120015928 | Amido Compounds And Their Use As Pharmaceuticals - The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess. | 2012-01-19 |
20120015929 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS - Disclosed herein are compounds of formula (I) | 2012-01-19 |
20120015930 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES - The present invention provides substituted imidazoheterocycles having the general structure of formula I: | 2012-01-19 |
20120015931 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE - The invention provides compounds having the general formula: | 2012-01-19 |
20120015932 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists - Indazole compounds, processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing such compounds and their use in therapy. | 2012-01-19 |
20120015933 | Spirocyclic nitriles as protease inhibitors - The invention relates to substituted carbo- and heterocyclic spiro compounds of the formula Ia which inhibit thiol proteases, to processes for their preparation and to the use thereof as medicaments. | 2012-01-19 |